CUSTOM SYNTHESIS AND TIDE FLUOR DYES
|Tide Fluor™- Dye||Absorption (TF)||Emission||ε||QY**||Optimum Tide Quencher™||Absorption (TQ)|
|Tide Fluor™ 1||345 nm||442 nm||20000||0.95||Tide Quencher™ 1||~490 nm|
|Tide Fluor™ 2||500 nm||527 nm||75000||0.9||Tide Quencher™ 2||~520 nm|
|Tide Fluor™ 2 WS||495 nm||518 nm||75000||0.9||Tide Quencher™ 2 WS|
|Tide Fluor™ 3||555 nm||584 nm||78000||0.85||Tide Quencher™ 3||~570 nm|
|Tide Fluor™ 3 WS||555 nm||565 nm||150000||0.10***||Tide Quencher™ 3 WS|
|Tide Fluor™ 4||590 nm||618 nm||90000||0.91||Tide Quencher™ 4 WS||~610 nm|
|Tide Fluor™ 5 WS||649 nm||664 nm||250000||0.25||Tide Quencher™ 5 WS||~670 nm|
|Tide Fluor™ 6 WS||649 nm||695 nm||220000||0.18||Tide Quencher™ 6 WS||~704 nm|
|Tide Fluor™ 7 WS||749 nm||775 nm||275000||0.12||Tide Quencher™ 7 WS||~763 nm|
|Tide Fluor™ 8 WS||775 nm||807 nm||250000||0.08||-||-|
* Extinction coefficient, determined at λmax (absorption maximum).
** Quantum yield in aqueous buffer (pH 7.2).
*** Fluorescence intensity is significantly increased when coupled to proteins or long peptides.
Tide FluorTM dyes and Tide QuencherTM dye labeled peptides are available as
• carboxylic acids
• maleimido-, azido- and alkyne- derivatives
• active esters (NHS)
Bachem offers a growing number of Tide FluorTM labeled dyes from stock as part of its catalog portfolio. Furthermore, we offer the labeling of products from our catalog with Tide FluorTM dyes as part of our custom synthesis service.
In addition to fluorescent dyes, Bachem offers a large selection of modifications as part of our catalog and custom synthesis service. A significant compilation is listed below
• Branched Peptides
• Cyclic Peptides
• Hydrocarbon-Stapled Peptides
• Maleimido and Clickable Peptides
• MAP Peptides
• Multiple Disulfide Bond Formation
• N- and C-terminal Modifications
• Non-natural Amino Acids
• Phosphorylation and Sulfation
For more details on Customs synthesis at Bachem, please consult our new brochure: please click here
For more details on Tide FluorTM dyes and fluorescent probes:
Fluorescently labeled peptides have the potential to make a positive impact on image-guided surgery and disease diagnosis. A technique of increasing interest involves the use of fluorescent peptide probes that bind or become modified by a molecular target overexpressed at the disease site. Some examples of fluorescently labeled peptides in the later stages of clinical stages of development for imaging applications are shown in Table 1.
|Product Name||Companies Involved||Highest Phase||Applications|
|AVB620||Avelas Biosciences Inc.||III||Breast Cancer|
|BLZ-100||Blaze Bioscience Inc.||III||Pediatric Central Nervous System Tumor|
|EMI-137||Edinburgh Molecular Imaging, University Medical Center Groningen||II||Barrett Esophagus,Esophageal Cancer,Dysplasia in Barrett Esophagus,Papillary Thyroid Cancer,Lymph Node Metastases, Colon Cancer|
Avelas Biosciences is focusing on the development of AVB-620, which is a cell penetrating peptide-fluorescent imaging agent designed to provide real-time cancer detection during surgery. The peptide undergoes proteolytic cleavage by matrix metalloproteinases (MMPs) that have higher activity in cancerous tissue. With cleavage, the fluorescent emission wavelength changes and fluorescent intensity increases, generating a ratiometric readout. AVB-620 is administered by intravenous infusion before surgery and imaging is performed with a near-infrared camera system to identify critical cancer margins (1). In 2018, Avelas presented initial results from the first part of a Phase II clinical trial of AVB-620 that demonstrated the potential of using AVB-620 during breast cancer surgery to identify malignant tissue and lymph nodes intraoperatively (2). The company completed a Phase II/III study of AVB-620 in the first half of 2020 and plans to announce topline data in the coming months (3). Additional cancer surgery applications for potential future exploration include ovarian, colorectal, lung, head and neck, melanoma and carcinoma.
Blaze Bioscience is developing BLZ-100 (tozuleristide) for use as a tumor-targeting optical imaging agent during cancer surgery for a range of cancer types including brain, breast, prostate, lung, colorectal and skin cancers. BLZ-100 is used to “paint” tumors in order to guide surgeons during the removal of cancerous tissue. The tumor paint consists of chlorotoxin, a tumor penetrating peptide, conjugated to indocyanine green dye, which emits light in the near-infrared range. In April 2020, the company announced that the U.S. Food and Drug Administration granted Fast Track designation to tozuleristide for pediatric central nervous system tumors (4). Currently, BLZ-100 is being evaluated in a Phase II/III clinical study in pediatric central nervous system tumors (5).
Edinburgh Molecular Imaging, a spin-off company from the University of Edinburgh, is developing EMI-137, an imaging agent that specifically targets the biomarker c-Met. EMI-137 is a 26 amino acid cyclic peptide conjugated with a modified cyanine 5 as the fluorescent dye (6). The company completed a Phase IIb clinical trial of EMI-137 in patients with suspected colorectal cancer in November 2019 (7). In addition to imaging colorectal cancer, EMI-137 is also being testing for other applications such as the diagnosis of cancers or for surgical margin delineation in breast, head, neck, and ovarian cancer.
Fluorescently labeled peptides are valuable tools for molecular imaging and over the past decade, more fluorescent peptide probes have been entering clinical trials. To support the development of labeled peptides for research and clinical applications, Bachem provides a one-stop shop for the custom synthesis of labeled peptides and amino acids. For custom synthesis, please contact our Custom Synthesis team to request a quote for your labeled peptide or amino acid.
1) S.L. Chen et al. Abstract P2-14-07: Use of an activatable cell penetrating peptide-fluorescent imaging agent (AVB-620) to identify positive and close margins intraoperatively, Cancer Research 79(4), P2-14-07 (2019)
2) Avelas Biosciences presents Phase II, Period 1 data in poster session at San Antonio Breast Cancer Symposium, Avelas Biosciences (2018)
3) Avelas and Axelarx announce collaboration to accelerate the development of promising nerve imaging agents, Avelas Biosciences (2020)
4) Blaze Bioscience announces FDA has granted Fast Track designation to BLZ-100, Blaze Bioscience (2020)
5) Study of tozuleristide and the Canvas Imaging System in pediatric subjects with CNS tumors undergoing surgery, ClinicalTrials.gov (2019)
6) S.A Esfahani et al. Optical imaging of mesenchymal epithelial transition factor (met) for enhanced detection and characterization of primary and metastatic hepatic tumors. Theranostics 6(12), 2028-2038 (2016)
7) Edinburgh Molecular Imaging commences Phase II European cancer trial, Edinburgh Molecular Imaging (2017)
My job title is Project Manager.
How long have you been with Bachem? Where did you work before Bachem?
I have been with Bachem since 2007. After 12 years as team leader QC, I took over my actual position at BD & Sales last year. Before joining Bachem, I worked for a big pharmaceutical company.
Briefly, what do you do at Bachem?
As project leader, I have the responsibility to initiate, coordinate and supervise the tasks and goals defined for the assigned projects.
What is your academic background/degrees or training?
I have a MSc degree in chemistry from the University of Basel and a Ph.D. from the Swiss Federal Institute of Technology of Zurich with a strong background in analytical chemistry.
What do you like to do outside of work?
Besides enjoying time with my family, I like to explore our beautiful landscape by mountain bike, to play the drums at the carnival of Basel and to observe the beautiful Swiss landscape from above with small airplanes.
What makes a perfect day for you?
The perfect day is when the project team has successfully achieved an important project goal and additionally when I could enjoy time with my family or one of my hobbies.
What do you like most about your job?
I mostly like the versatility of my function, the exchange with the customers and the possibility to promote successfully the projects together with my project team colleagues.
What is your preferred peptide?
Due to the recently approved new pharmaceutical application forms, the corresponding benefits for the affected patients and the positive development for Bachem, my preferred peptide is Glucagon.
Thank you very much Stefano.
Interesting news about peptides in basic research and pharmaceutical development: